Z
ZENAS BIOPHARMA, INC. COMMON STOCK
NASDAQ: ZBIO (Zenas BioPharma, Inc.)
Kemas kini terakhir: semalam, 1:11AM19.36
0.04 (0.21%)
| Penutupan Terdahulu | 19.32 |
| Buka | 19.23 |
| Jumlah Dagangan | 786,596 |
| Purata Dagangan (3B) | 769,662 |
| Modal Pasaran | 1,207,503,488 |
| Harga / Jualan (P/S) | 78.59 |
| Harga / Buku (P/B) | 4.53 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -373.30% |
| EPS Cair (TTM) | -3.89 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.43% |
| Nisbah Semasa (MRQ) | 6.47 |
| Aliran Tunai Operasi (OCF TTM) | -137.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -77.73 M |
| Pulangan Atas Aset (ROA TTM) | -56.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Zenas BioPharma, Inc. | Menurun | Menurun |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.13 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 21.20% |
| % Dimiliki oleh Institusi | 74.88% |
| Julat 52 Minggu | ||
| Median | 44.00 (127.27%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Feb 2026 | 44.00 (127.27%) | Beli | 21.48 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |